Given the potent antitumor activity of MGD-A7 and MGD-C9 in multiple hematological cancer cells, we sought to explore the potential interaction modes between these compounds and the CRBN protein at the molecular level through molecular docking. This evidence concerns the gene CRBN and hematopoietic and lymphoid cell neoplasm.